Biological targeting and activity of pre-fibrillar Aβ assemblies

Non-fibrillar Amyloidogenic Protein Assemblies - Common Cytotoxins Underlying Degenerative Diseases

Volumn 9789400727748, Issue , 2012, Pages 103-133

  Wilcox, Kyle C ^a   Pitt, Jason ^a   Sebollela, Adriano ^a   Martirosova, Helen ^a   Lacor, Pascale N ^a   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Alzheimer's therapeutics; A oligomers; Insulin signaling

Indexed keywords

EID: 84931470212     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-2774-8_4     Document Type: Chapter

References (193)

1. Abbott MA, Wells DG, Fallon JR (1999) The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 19:7300-7308
2. Ahmadian G, Ju W, Liu L, Wyszynski M, Lee SH, Dunah AW, Taghibiglou C, Wang Y, Lu J, Wong TP, Sheng M, Wang YT (2004) Tyrosine phosphorylation of GluR2 is required for insulinstimulated AMPA receptor endocytosis and LTD. EMBO J 23:1040-1050
3. Aizenman Y, Weichsel ME Jr, De Vellis J (1986) Changes in insulin and transferrin requirements of pure brain neuronal cultures during embryonic development. Proc Natl Acad Sci USA 83:2263-2266
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, Mcgeer PL, O'banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421
5. Alarcon JM, Brito JA, Hermosilla T, Atwater I, Mears D, Rojas E (2006) Ion channel formation by Alzheimer's disease amyloid b-peptide (A b 40) in unilamellar liposomes is determined by anionic phospholipids. Peptides 27:95-104
6. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118:167-179
7. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G (2010) Synthetic amyloid-b oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 107:2295-2300
8. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005) Globular amyloid b-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847
9. Bayer TA, Wirths O (2010) Intracellular accumulation of amyloid-b -a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci 2:8
10. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H (2001) Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature 411:801-805
11. Bazoti FN, Bergquist J, Markides KE, Tsarbopoulos A (2006) Noncovalent interaction between amyloid-b-peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 17:568-575
12. Bazoti FN, Bergquist J, Markides K, Tsarbopoulos A (2008) Localization of the noncovalent binding site between amyloid-b-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. J Am Soc Mass Spectrom 19:1078-1085
13. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB, Breslin PA (2005) Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 437:45-46
14. Benito E, Barco A (2010) CREB's control of intrinsic and synaptic plasticity: Implications for CREB-dependent memory models. Trends Neurosci 33:230-240
15. Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT (2009) The PI3KAkt-mTOR pathway regulates A b oligomer induced neuronal cell cycle events. Mol Neurodegener 4:14
16. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid b-protein (A b ) assembly: A b 40 and A b 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100:330-335
17. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613
18. Boutaud O, Montine TJ, Chang L, Klein WL, Oates JA (2006) PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid b 1-42. J Neurochem 96:917-923
19. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259
20. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-b, and Tau: effects on cognitive impairments. J Biol Chem 285:13107-13120
21. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A (2010) Prion protein and A b-related synaptic toxicity impairment. EMBO Mol Med 2:306-314
22. Chang L, Bakhos L, Wang Z, Venton DL, Klein WL (2003) Femtomole immunodetection of synthetic and endogenous amyloid-b oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci 20:305-313
23. Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24:4692-4697
24. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25:9694-9703
25. Chiu SL, Chen CM, Cline HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58:708-719
26. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of A b (1-42) into globular neurotoxins. Biochemistry 42:12749-12760
27. Citri A, Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33:18-41
28. Clarke DW, Boyd FT Jr, Kappy MS, Raizada MK (1984) Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain. J Biol Chem 259:11672-11675
29. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-b protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
30. Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer's disease. Neurobiol Dis 35:128-140
31. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A b oligomerization. FASEB J 18:1366-1372
32. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) A b oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601
33. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL (2008) Alzheimer's diseasetype neuronal tau hyperphosphorylation induced by A b oligomers. Neurobiol Aging 29:1334-1347
34. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A b oligomers. Proc Natl Acad Sci USA 106:1971-1976
35. Decker H, Lo KY, Unger SM, Ferreira ST, Silverman MA (2010) Amyloid-b peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3 b in primary cultured hippocampal neurons. J Neurosci 30:9166-9171
36. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J (2009) A role for synaptic zinc in activity-dependent A b oligomer formation and accumulation at excitatory synapses. J Neurosci 29:4004-4015
37. Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, Reese LC, Taglialatela G (2010) Amyloid-b oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 88:2923-2932
38. Douglass AD, Vale RD (2005) Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T cells. Cell 121:937-950
39. Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL, Li M (2008) Salvianolic acid B inhibits A b fibril formation and disaggregates preformed fibrils and protects against A b-induced cytotoxicity. Neurochem Int 52:741-750
40. Eckert A, Hauptmann S, Scherping I, Meinhardt J, Rhein V, Drose S, Brandt U, Fandrich M, Muller WE, Gotz J (2008) Oligomeric and fibrillar species of b-amyloid (A b 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med 86:1255-1267
41. Erol A (2009) Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 17:267-276
42. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D (2009) Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379:406-410
43. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez De Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A, Del Rio J, Frechilla D (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35:1593-1604
44. Feng Y, Yang SG, Du XT, Zhang X, Sun XX, Zhao M, Sun GY, Liu RT (2009) Ellagic acid promotes A b 42 fibrillization and inhibits A b 42-induced neurotoxicity. Biochem Biophys Res Commun 390:1250-1254
45. Fernandes ML, Saad MJ, Velloso LA (2001) Effects of age on elements of insulin-signaling pathway in central nervous system of rats. Endocrine 16:227-234
46. Fonseca AC, Resende R, Oliveira CR, Pereira CM (2010) Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 223:282-293
47. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW (2006) Functional amyloid formation within mammalian tissue. PLoS Biol 4:e6
48. Frackowiak J, Zoltowska A, Wisniewski HM (1994) Non-fibrillar b-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J Neuropathol Exp Neurol 53:637-645
49. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) High-molecular-weight b-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24:2716-2726
50. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-b oligomers. Ann Neurol 68:220-230
51. Geng L, Zhang HL, Peng HB (2009) The formation of acetylcholine receptor clusters visualized with quantum dots. BMC Neurosci 10:80
52. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102:2273-2276
53. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A (2009) b-Amyloid monomers are neuroprotective. J Neurosci 29:10582-10587
54. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A b ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422
55. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal A b 42 accumulation in human brain. Am J Pathol 156:15-20
56. Grace EA, Busciglio J (2003) Aberrant activation of focal adhesion proteins mediates fibrillar amyloid b-induced neuronal dystrophy. J Neurosci 23:493-502
57. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411-418
58. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'connor R, O'neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93:105-117
59. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubuleassociated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261:6084-6089
60. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat Rev Mol Cell Biol 8:101-112
61. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884
62. Havrankova J, Roth J, Brownstein M (1978a) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272:827-829
63. Havrankova J, Schmechel D, Roth J, Brownstein M (1978b) Identification of insulin in rat brain. Proc Natl Acad Sci USA 75:5737-5741
64. Hawkes CA, Deng LH, Shaw JE, Nitz M, Mclaurin J (2010) Small molecule b-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. Eur J Neurosci 31:203-213
65. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B (2009) Deaths: final data for 2006. Natl Vital Stat Rep 57:1-134
66. Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp JA (1997) Inhibition of the electrostatic interaction between b-amyloid peptide and membranes prevents b-amyloid-induced toxicity. Proc Natl Acad Sci USA 94:9412-9416
67. Herukka SK, Hallikainen M, Soininen H, Pirttila T (2005) CSF A b 42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64:1294-1297
68. Heurtaux T, Michelucci A, Losciuto S, Gallotti C, Felten P, Dorban G, Grandbarbe L, Morga E, Heuschling P (2010) Microglial activation depends on b-amyloid conformation: role of the formylpeptide receptor 2. J Neurochem 114:576-586
69. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, Nolte MW, Perez-Cruz C, Van Der Auwera I, Van Leuven F, Van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U (2010) Generation and therapeutic efficacy of highly oligomer-specific b-amyloid antibodies. J Neurosci 30:10369-10379
70. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies A b-induced synaptic depression and dendritic spine loss. Neuron 52:831-843
71. Huang CC, Lee CC, Hsu KS (2004) An investigation into signal transduction mechanisms involved in insulin-induced long-term depression in the CA1 region of the hippocampus. J Neurochem 89:217-231
72. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 142:387-397
73. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86:3265-3274
74. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E (2010) Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 223:422-431
75. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (2009) Amyloid-b dynamics are regulated by orexin and the sleep-wake cycle. Science 326:1005-1007
76. Kayed R, Head E, Thompson JL, Mcintire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489
77. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4:e7917
78. Kemp N, Bashir ZI (2001) Long-term depression: A cascade of induction and expression mechanisms. Prog Neurobiol 65:339-365
79. Kessels HW, Nguyen LN, Nabavi S, Malinow R (2010) The prion protein as a receptor for amyloid-b. Nature 466:E3-E4, discussion E4-5
80. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) a 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A b-amyloid-induced neurotoxicity. J Biol Chem 276:13541-13546
81. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid b protein. FASEB J 17:118-120
82. Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T (2009) CCL2 accelerates microglia-mediated A b oligomer formation and progression of neurocognitive dysfunction. PLoS One 4:e6197
83. Klein WL (2002) A b toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41:345-352
84. Klein WL, Krafft GA, Finch CE (2001) Targeting small A b oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24:219-224
85. Klein WL, Lacor PN, De Felice FG, Ferreira ST (2007) Molecules that disrupt memory circuits in Alzheimer's disease: the attack on synapses by A b oligomers (ADDLs). In: Bontempi B, Silva AJ, Christen Y (eds) Memories: molecules and Circuits. Springer, Berlin/Heidelberg
86. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL (2009) Oligomeric amyloid b associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012-4017
87. Korolainen MA, Nyman TA, Aittokallio T, Pirttila T (2010) An update on clinical proteomics in Alzheimer's research. J Neurochem 112:1386-1414
88. Kovacs GG, Head MW, Hegyi I, Bunn TJ, Flicker H, Hainfellner JA, Mccardle L, Laszlo L, Jarius C, Ironside JW, Budka H (2002) Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol 12:1-11
89. Krafft GA, Klein WL (2010) ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology 59:230-242
90. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble A b (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081
91. Lacor PN (2007) Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics 8:486-508
92. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid b oligomers. J Neurosci 24:10191-10200
93. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) A b oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807
94. Laferla FM, Green KN, Oddo S (2007) Intracellular amyloid-b in Alzheimer's disease. Nat Rev Neurosci 8:499-509
95. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from A b 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
96. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001) Vaccination with soluble A b oligomers generates toxicity-neutralizing antibodies. J Neurochem 79:595-605
97. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL (2007) Monoclonal antibodies that target pathological assemblies of A b. J Neurochem 100:23-35
98. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid b-derived neurotoxins. CNS Neurol Disord Drug Targets 8:65-81
99. Larson J, Lynch G, Games D, Seubert P (1999) Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840:23-35
100. Lashuel HA, Lansbury PT Jr (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39:167-201
101. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-b oligomers. Nature 457:1128-1132
102. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2010) Nature 466:E4-E5
103. Laurén et al. reply Lee CC, Huang CC, Wu MY, Hsu KS (2005) Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J Biol Chem 280:18543-18550
104. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid-b peptide (A b ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A b precursor protein (APP) transgenic mice. J Biol Chem 281:4292-4299
105. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracellular b-amyloid. Mol Biol Cell 20:1533-1544
106. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPAR g ). J Biol Chem 270:12953-12956
107. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'brien PC, Palumbo PJ (1997) The risk of dementia among persons with diabetes mellitus: A population-based cohort study. Ann NY Acad Sci 826:422-427
108. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, Dewilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC (2010) A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-b-associated cognitive impairment. J Alzheimers Dis 20:113-126
109. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-b protein assembly in the brain impairs memory. Nature 440:352-357
110. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, Van Duinen SG, Bots GT, Luyendijk W, Frangione B (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124-1126
111. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009a) Soluble oligomers of amyloid b protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62:788-801
112. Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB 3rd, Lee VM (2009b) Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem 110:1339-1351
113. Lieberman DN, Mody I (1999) Casein kinase-II regulates NMDA channel function in hippocampal neurons. Nat Neurosci 2:125-132
114. Lorenzo A, Yankner BA (1994) b-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:12243-12247
115. Malchiodi-Albedi F, Contrusciere V, Raggi C, Fecchi K, Rainaldi G, Paradisi S, Matteucci A, Santini MT, Sargiacomo M, Frank C, Gaudiano MC, Diociaiuti M (2010) Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. Biochim Biophys Acta 1802:406-415
116. Man HY, Lin JW, Ju WH, Ahmadian G, Liu L, Becker LE, Sheng M, Wang YT (2000) Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron 25:649-662
117. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, Mandelkow E (1992) Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 314:315-321
118. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009) Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 29:6734-6751
119. Mckee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, Laferla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces A b, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207:225-236
120. Mclaurin J, Chakrabartty A (1997) Characterization of the interactions of Alzheimer b-amyloid peptides with phospholipid membranes. Eur J Biochem 245:355-363
121. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC (2010) Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol 119:567-577
122. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M (2009) Isolation and characterization of patientderived, toxic, high mass amyloid b-protein (A b ) assembly from Alzheimer disease brains. J Biol Chem 284:32895-32905
123. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee HG, Zhu X, Smith MA, Perry G (2010) Intraneuronal amyloid b accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 37:731-737
124. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE (1994) Purification and characterization of brain clusterin. Biochem Biophys Res Commun 204:1131-1136
125. Oddo S, Caccamo A, Kitazawa M, Tseng BP, Laferla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24:1063-1070
126. Oddo S, Billings L, Kesslak JP, Cribbs DH, Laferla FM (2004) A b immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332
127. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, Laferla FM (2006) Temporal profile of amyloid-b (A b ) oligomerization in an in vivo model of Alzheimer disease. A link between A b and tau pathology. J Biol Chem 281:1599-1604
128. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, Teplow DB (2008) Effects of grape seed-derived polyphenols on amyloid b-protein self-assembly and cytotoxicity. J Biol Chem 283:32176-32187
129. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53:1937-1942
130. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O (2009) Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 109:1800-1811
131. Peila R, Rodriguez BL, White LR, Launer LJ (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63:228-233
132. Pitt J, Roth W, Lacor P, Smith AB 3rd, Blankenship M, Velasco P, De Felice F, Breslin P, Klein WL (2009) Alzheimer's-associated A b oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 240:189-197
133. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S (2010) Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 A b PP-overexpressing mice. J Alzheimers Dis 19:691-704
134. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid b-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270:9564-9570
135. Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795-811
136. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A (2010) Deleterious effects of amyloid b oligomers acting as an extracellular scaffold for mGluR5. Neuron 66:739-754
137. Resende R, Ferreiro E, Pereira C, Resende De Oliveira C (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-b peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155:725-737
138. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF (2004) Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15:955-959
139. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mildto-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254
140. Roher AE, Ball MJ, Bhave SV, Wakade AR (1991) b-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun 174:572-579
141. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61:1916-1926
142. Ryu BR, Ko HW, Jou I, Noh JS, Gwag BJ (1999) Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J Neurobiol 39:536-546
143. Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of A b oligomers. FEBS J 277:1348-1358
144. Serrano F, Klann E (2004) Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev 3:431-443
145. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842
146. Shirazi SK, Wood JG (1993) The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 4:435-437
147. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A (2006) Amyloid b peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33:274-282
148. Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, Wolfe AL, Matthews M, Heidecker GJ, Joyce JG, Villarreal SA, Kinney GG (2010) Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 31:189-202
149. Simonyi A, Schachtman TR, Christoffersen GR (2005) The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18:353-361
150. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347:1141-1145
151. Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L (2009) The role of A b-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 16:225-233
152. Smith AB 3rd, Han Q, Breslin PA, Beauchamp GK (2005) Synthesis and assignment of absolute configuration of leocanthal: A potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils. Org Lett 7:5075-5078
153. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR (1996) Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275:528-532
154. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-b. Nat Neurosci 8:1051-1058
155. Sun Y, Zhang G, Hawkes CA, Shaw JE, Mclaurin J, Nitz M (2008a) Synthesis of scyllo-inositol derivatives and their effects on amyloid b peptide aggregation. Bioorg Med Chem 16:7177-7184
156. Sun ZK, Yang HQ, Pan J, Zhen H, Wang ZQ, Chen SD, Ding JQ (2008b) Protective effects of erythropoietin on tau phosphorylation induced by b-amyloid. J Neurosci Res 86:3018-3027
157. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK (2004) Oligomerization of Alzheimer's b-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24:3592-3599
158. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A b deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107:7036-7041
159. Tan SE, Wenthold RJ, Soderling TR (1994) Phosphorylation of AMPA-type glutamate receptors by calcium/calmodulin-dependent protein kinase II and protein kinase C in cultured hippocampal neurons. J Neurosci 14:1123-1129
160. Tanaka M, Sawada M, Yoshida S, Hanaoka F, Marunouchi T (1995) Insulin prevents apoptosis of external granular layer neurons in rat cerebellar slice cultures. Neurosci Lett 199:37-40
161. Tchantchou F, Lacor PN, Cao Z, Lao L, Hou Y, Cui C, Klein WL, Luo Y (2009) Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis 18:787-798
162. Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580
163. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35:352-358
164. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008) A new amyloid b variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63:377-387
165. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid b oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30:4845-4856
166. Tong L, Thornton PL, Balazs R, Cotman CW (2001) b-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem 276:17301-17306
167. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesné S, O'hare E, Walsh DM, Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-b oligomers. Ann Neurol 60:668-676
168. Townsend M, Mehta T, Selkoe DJ (2007) Soluble A b inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282:33305-33312
169. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, Worley PF (1999) Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23:583-592
170. Van Der Heide LP, Ramakers GM, Smidt MP (2006) Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 79:205-221
171. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB (1993) Characterization of b-amyloid peptide from human cerebrospinal fluid. J Neurochem 61:1965-1968
172. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid b-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831-10839
173. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416:535-539
174. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of b amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133-140
175. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004a) Block of long-term potentiation by naturally secreted and synthetic amyloid b-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogenactivated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378
176. Wang Z, Chang L, Klein WL, Thatcher GR, Venton DL (2004b) Per-6-substituted-per-6-deoxy b-cyclodextrins inhibit the formation of b-amyloid peptide derived soluble oligomers. J Med Chem 47:3329-3333
177. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM (2008) Grape-derived polyphenolics prevent A b oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28:6388-6392
178. Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, Li JL, Du XT, Lambert MP, Yang SG, Zhao M, Klein WL, Liu RT (2009) Conformation-dependent single-chain variable fragment antibodies specifically recognize b-amyloid oligomers. FEBS Lett 583:579-584
179. Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, Xiang YK (2010) Binding of amyloid b peptide to b 2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J 24:3511-3521
180. West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344:769-772
181. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ (2005) Differential effects of oligomeric and fibrillar amyloid-b 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18:459-465
182. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against A b in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24
183. Wong PT, Schauerte JA, Wisser KC, Ding H, Lee EL, Steel DG, Gafni A (2009) Amyloid-b membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J Mol Biol 386:81-96
184. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-b-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102-13113
185. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid b oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901
186. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D, Walter K, Johnson RW, Hajduk PJ, Olejniczak ET (2009) Structural characterization of a soluble amyloid b-peptide oligomer. Biochemistry 48:1870-1877
187. Zampagni M, Evangelisti E, Cascella R, Liguri G, Becatti M, Pensalfini A, Uberti D, Cenini G, Memo M, Bagnoli S, Nacmias B, Sorbi S, Cecchi C (2010) Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med 88:597-608
188. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller DE (1996a) Insulin-and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271:31771-31774
189. Zhang C, Qiu HE, Krafft GA, Klein WL (1996b) A b peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line. Neurosci Lett 211:187-190
190. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid b oligomers induce impairment of neuronal insulin receptors. FASEB J 22:246-260
191. Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A b. J Biol Chem 284:18742-18753
192. Zhao WQ, Santini F, Breese R, Ross D, Zhang XD, Stone DJ, Ferrer M, Townsend M, Wolfe AL, Seager MA, Kinney GG, Shughrue PJ, Ray WJ (2010) Inhibition of calcineurin-mediated endocytosis and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid b oligomer-induced synaptic disruption. J Biol Chem 285:7619-7632
193. Zhuo JM, Prakasam A, Murray ME, Zhang HY, Baxter MG, Sambamurti K, Nicolle MM (2008) An increase in A b 42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. Curr Alzheimer Res 5:385-391